Tessa M. Bosch

1.4k total citations
33 papers, 953 citations indexed

About

Tessa M. Bosch is a scholar working on Pediatrics, Perinatology and Child Health, Oncology and Molecular Biology. According to data from OpenAlex, Tessa M. Bosch has authored 33 papers receiving a total of 953 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pediatrics, Perinatology and Child Health, 12 papers in Oncology and 8 papers in Molecular Biology. Recurrent topics in Tessa M. Bosch's work include Drug Transport and Resistance Mechanisms (10 papers), Pharmacological Effects and Toxicity Studies (8 papers) and Pharmacogenetics and Drug Metabolism (7 papers). Tessa M. Bosch is often cited by papers focused on Drug Transport and Resistance Mechanisms (10 papers), Pharmacological Effects and Toxicity Studies (8 papers) and Pharmacogenetics and Drug Metabolism (7 papers). Tessa M. Bosch collaborates with scholars based in Netherlands, United States and Germany. Tessa M. Bosch's co-authors include Jan H.M. Schellens, Jos H. Beijnen, Irma Meijerman, Paul H.M. Smits, Valerie D. Doodeman, Gert Luurtsema, Eric J. F. Franssen, Mark Lubberink, Adriaan A. Lammertsma and Ruud Oerlemans and has published in prestigious journals such as Clinical Cancer Research, British Journal of Cancer and Annals of the Rheumatic Diseases.

In The Last Decade

Tessa M. Bosch

31 papers receiving 936 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tessa M. Bosch Netherlands 17 411 278 186 164 85 33 953
Venkatesh Pilla Reddy United States 19 305 0.7× 325 1.2× 207 1.1× 130 0.8× 118 1.4× 56 1.1k
Sun-Young Ahn United States 18 439 1.1× 442 1.6× 168 0.9× 237 1.4× 30 0.4× 46 1.5k
Tore Bjerregaard Stage Denmark 22 424 1.0× 382 1.4× 223 1.2× 166 1.0× 41 0.5× 69 1.2k
Amy Price United Kingdom 6 200 0.5× 406 1.5× 302 1.6× 224 1.4× 71 0.8× 12 1.3k
Rujia Xie United States 16 659 1.6× 384 1.4× 235 1.3× 300 1.8× 129 1.5× 32 1.2k
Géraldine M. Ferron United States 19 231 0.6× 303 1.1× 278 1.5× 210 1.3× 138 1.6× 28 1.1k
Koujirou Yamamoto Japan 22 403 1.0× 267 1.0× 493 2.7× 165 1.0× 83 1.0× 102 1.4k
Nobuko Ohmoto Japan 11 470 1.1× 188 0.7× 165 0.9× 252 1.5× 45 0.5× 13 774
Andrew Crowe Australia 18 333 0.8× 207 0.7× 91 0.5× 214 1.3× 66 0.8× 41 1.1k
Fen Jiang China 15 252 0.6× 131 0.5× 191 1.0× 109 0.7× 31 0.4× 58 847

Countries citing papers authored by Tessa M. Bosch

Since Specialization
Citations

This map shows the geographic impact of Tessa M. Bosch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tessa M. Bosch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tessa M. Bosch more than expected).

Fields of papers citing papers by Tessa M. Bosch

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tessa M. Bosch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tessa M. Bosch. The network helps show where Tessa M. Bosch may publish in the future.

Co-authorship network of co-authors of Tessa M. Bosch

This figure shows the co-authorship network connecting the top 25 collaborators of Tessa M. Bosch. A scholar is included among the top collaborators of Tessa M. Bosch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tessa M. Bosch. Tessa M. Bosch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kuijper, T. Martijn, et al.. (2023). Cost–utility analysis of tapering strategies of biologicals in rheumatoid arthritis patients in the Netherlands. Annals of the Rheumatic Diseases. 82(10). 1–11. 4 indexed citations
2.
Doorn, Leni van, Esther Oomen‐de Hoop, Tessa M. Bosch, et al.. (2021). The added value of H2 antagonists in premedication regimens during paclitaxel treatment. British Journal of Cancer. 124(10). 1647–1652. 15 indexed citations
3.
Bosch, Tessa M., et al.. (2021). Chronic kidney disease in lithium-treated patients, incidence and rate of decline. International Journal of Bipolar Disorders. 9(1). 1–1. 23 indexed citations
4.
Beck, Olof, Tessa M. Bosch, Nadia Fucci, et al.. (2017). European guidelines for workplace drug testing in oral fluid. Drug Testing and Analysis. 10(3). 402–415. 24 indexed citations
5.
Beck, Olof, Tessa M. Bosch, Nadia Fucci, et al.. (2017). European guidelines for workplace drug testing in urine. Drug Testing and Analysis. 9(6). 853–865. 37 indexed citations
6.
Hoekstra, Rocco, et al.. (2014). [Lithium: only acceptable with careful monitoring].. PubMed. 158. A7207–A7207. 1 indexed citations
7.
Bosch, Tessa M.. (2008). Pharmacogenomics of Drug-Metabolizing Enzymes and Drug Transporters in Chemotherapy. Methods in molecular biology. 448. 63–76. 35 indexed citations
8.
Cornelissen, Marion, Nico Kloosterboer, Kristel M. L. Crommentuyn, et al.. (2007). Antiviral Activity of HIV Type 1 Protease Inhibitors Nelfinavir and Indinavir in Vivo Is Not Influenced by P-Glycoprotein Activity on CD4 + T Cells. AIDS Research and Human Retroviruses. 23(1). 19–27. 6 indexed citations
9.
Bosch, Tessa M., et al.. (2007). Rapid Detection of the DPYD IVS14+1G>A Mutation for Screening Patients to Prevent Fluorouracil-Related Toxicity. Molecular Diagnosis & Therapy. 11(2). 105–108. 9 indexed citations
10.
Bosch, Tessa M., Valerie D. Doodeman, Paul H.M. Smits, et al.. (2006). Pharmacogenetic Screening for Polymorphisms in Drug-Metabolizing Enzymes and Drug Transporters in a Dutch Population. Molecular Diagnosis & Therapy. 10(3). 175–185. 24 indexed citations
11.
Bosch, Tessa M., Alwin D. R. Huitema, Valerie D. Doodeman, et al.. (2006). Pharmacogenetic Screening of CYP3A and ABCB1 in Relation to Population Pharmacokinetics of Docetaxel. Clinical Cancer Research. 12(19). 5786–5793. 107 indexed citations
12.
Bosch, Tessa M., Maarten J. Deenen, Paul H.M. Smits, et al.. (2006). Screening for polymorphisms in the PXR gene in a Dutch population. European Journal of Clinical Pharmacology. 62(5). 395–399. 25 indexed citations
13.
Bosch, Tessa M., Irma Meijerman, Jos H. Beijnen, & Jan H.M. Schellens. (2006). Genetic Polymorphisms of Drug-Metabolising Enzymes and Drug Transporters in the Chemotherapeutic Treatment of Cancer. Clinical Pharmacokinetics. 45(3). 253–285. 133 indexed citations
14.
Luurtsema, Gert, Mark Lubberink, Tessa M. Bosch, et al.. (2006). Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[11C]verapamil and positron emission tomography. Clinical Pharmacology & Therapeutics. 79(6). 540–548. 141 indexed citations
15.
Bosch, Tessa M., Bobby P. C. Koeleman, Jan H.M. Schellens, et al.. (2005). Detection of Single Nucleotide Polymorphisms in the ABCG2 Gene in a Dutch Population. PubMed. 5(2). 123–131. 42 indexed citations
16.
Khalturin, Konstantin, et al.. (2005). Towards a molecular code for individuality in the absence of MHC: screening for individually variable genes in the urochordate. Developmental & Comparative Immunology. 29(9). 759–773. 14 indexed citations
17.
18.
Kuppens, I. E. L. M., Tessa M. Bosch, M. J. van Maanen, et al.. (2004). Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093). Cancer Chemotherapy and Pharmacology. 55(1). 72–78. 72 indexed citations
19.
Khalturin, Konstantin, et al.. (2004). Recognition strategies in the innate immune system of ancestral chordates. Molecular Immunology. 41(11). 1077–1087. 41 indexed citations
20.
Bosch, Tessa M., Tjip S. van der Werf, Donald R. A. Uges, et al.. (2000). Antidepressants self-poisoning and ICU admissions in a university hospital in The Netherlands.. Pharmacy World & Science. 22(3). 92–95. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Venkatesh Pilla Reddy Breakdown of academic impact, for papers by Sun-Young Ahn Breakdown of academic impact, for papers by Tore Bjerregaard Stage Breakdown of academic impact, for papers by Amy Price Breakdown of academic impact, for papers by Rujia Xie Breakdown of academic impact, for papers by Géraldine M. Ferron Breakdown of academic impact, for papers by Koujirou Yamamoto Breakdown of academic impact, for papers by Nobuko Ohmoto Breakdown of academic impact, for papers by Andrew Crowe Breakdown of academic impact, for papers by Fen Jiang
Rankless by CCL
2026